Dr. Ronald F. Tutrone Jr., MD

Dr. Tutrone practices at Summit Ambulatory Surgical Center, LLC in Towson, Maryland.

Dr. Tutrone's NPI, 1265495204, was assigned on April 10, 2006. Dr. Tutrone graduated from Rutgers New Jersey Medical School in 1987. Dr. Tutrone holds Maryland license D44467.

Dr. Tutrone's primary practice is Summit Ambulatory Surgical Center, LLC, at 6535 N Charles St, Towson, MD 21204 in Baltimore County. The practice phone is (410) 825-5454.

Dr. Tutrone's primary practice is Summit Ambulatory Surgical Center, LLC in Towson, Maryland. Dr. Tutrone is also affiliated with Greater Baltimore Medical Center. The medical group on file is Chesapeake Urology Associates. Dmand AI also links Dr. Tutrone to 1 more group practice or clinic, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Tutrone practices, 2 sites in all. Vendor and product names are available with a free account.

Urology is Dr. Tutrone's primary specialty in the NPI Registry, under taxonomy code 208800000X. Dr. Tutrone is licensed in Maryland.

CMS data shows 5,126 Medicare services from Dr. Tutrone across 14 procedure codes in 2024, for 340 Medicare patients. Medicare paid $149,670 for them. Every service was in an office.

CMS counts 340 Medicare patients who saw Dr. Tutrone in 2024. The largest group is 75 to 84, with 156 patients. 75% of them have high blood pressure, and 75% have high cholesterol. Their average risk score is 1.17, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Dr. Tutrone's median patient age at 77, with 8% women.

In 2024, Dr. Tutrone wrote 1,199 Medicare Part D claims for 254 patients. 85% of them were for generic drugs. CMS names the drug for 1,083 of them, across 20 drugs with 11 or more claims each, at $1,299,670 in total drug cost. In 2023, CMS named 1,075 claims across 18 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 100 out of 100 for Dr. Tutrone for performance year 2024, reported as part of a group. Dr. Tutrone accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links 45 papers to Dr. Tutrone, published from 2014 to 2025. 2023 was the busiest year, with 7. The most frequent topics are Prostatic Neoplasms, Prostate-Specific Antigen and Prostatic Neoplasms, Castration-Resistant. Dr. Tutrone has published most often in Prostate Cancer Prostatic Dis. Dr. Tutrone's most frequent co-authors are Daniel R. Saltzstein, MD, Michael Cookson, MD and Christopher M. Pieczonka, MD.

Dmand AI links Dr. Tutrone to 1 clinical trial. 1 is still active or recruiting. Conditions studied include Neoplasm Metastasis and Neoplastic Processes. Open Payments lists research payments to Dr. Tutrone that name 2 trials.

CMS Open Payments shows 637 general payments to Dr. Tutrone from 55 drug and device companies from 2016 to 2025. Speaker and faculty fees make up the largest share, 50% of the total. Astellas Pharma US Inc paid the most, $41,805. It also lists 36 research payments totaling $83,109 from 2022 to 2025, naming 2 clinical trials.

Dr. Tutrone graduated from Rutgers New Jersey Medical School in 1987.